Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Payables (2016 - 2025)

Historic Payables for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $4.8 million.

  • Altimmune's Payables rose 32400.71% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year increase of 32400.71%. This contributed to the annual value of $211000.0 for FY2024, which is 8980.68% down from last year.
  • Latest data reveals that Altimmune reported Payables of $4.8 million as of Q3 2025, which was up 32400.71% from $851000.0 recorded in Q2 2025.
  • Over the past 5 years, Altimmune's Payables peaked at $5.2 million during Q1 2023, and registered a low of $6083.0 during Q3 2021.
  • Over the past 5 years, Altimmune's median Payables value was $2.1 million (recorded in 2023), while the average stood at $2.3 million.
  • Its Payables has fluctuated over the past 5 years, first crashed by 9930.47% in 2021, then skyrocketed by 2322730.56% in 2022.
  • Quarter analysis of 5 years shows Altimmune's Payables stood at $2.0 million in 2021, then surged by 136.18% to $4.8 million in 2022, then plummeted by 56.91% to $2.1 million in 2023, then crashed by 89.81% to $211000.0 in 2024, then skyrocketed by 2176.78% to $4.8 million in 2025.
  • Its Payables stands at $4.8 million for Q3 2025, versus $851000.0 for Q2 2025 and $1.1 million for Q1 2025.